Meropenem Qilu (Meropenem Anhydrous)

Meropenem belongs to the carbapenem class and exerts its effect by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, weakening the wall and causing bacterial cell lysis, which results in a rapid bactericidal action against a wide range of pathogens.

The dosage of Meropenem Qilu is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Dosing regimens are individualized and should follow the prescriber's instructions and institutional protocols.

Safety data for Meropenem in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Qilu product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Meropenem shares the broad‑spectrum activity typical of carbapenems but offers a slightly broader Gram‑positive coverage compared with imipenem and a lower propensity for inducing seizures than ertapenem. Choice among carbapenems depends on local resistance patterns, infection site, dosing convenience, and patient‑specific factors.

Meropenem Qilu should be stored at 2‑8 °C in a refrigerator, protected from light. The product must not be frozen or shaken. Maintaining the cold‑chain ensures stability and potency until the time of reconstitution for intravenous administration.

Meropenem Qilu is supplied as a sterile powder for injection. It is reconstituted with a suitable diluent and administered intravenously over a short infusion period, typically 15‑30 minutes, as directed by the prescribing clinician. Administration should follow aseptic technique and institutional infusion protocols.

Serious adverse events include seizures, especially in patients with pre‑existing CNS disorders or renal impairment, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and management of these reactions are essential, and patients should be monitored closely during therapy.

Meropenem Qilu is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, as the drug may reduce valproate levels.